Digest Network Come funziona
Network
/
Società
Ad
Non verificato

Adcendo

Di cosa scriviamo

BiologiaEconomiaFarmaceuticaFinanzaSanità

6 comunicati stampa

Guarda tutti i comunicati
23/04/2025
Farmaceutica
Sanità
Finanza
Biologia
Adcendo ApS to Present Data on its Clinical Stage ADCs ADCE-T02 and ADCE-D01 at the 2025 American Association for Cancer Research (AACR) Annual Meeting
Fonte
Adcendo
Emittente
PR News Wire
1.00
0
01/04/2025
Farmaceutica
Sanità
Economia
Management
Organizzazione Aziendale
Biologia
Adcendo ApS Announces Changes in Board of Directors and Strengthens Executive Leadership Team
Fonte
Adcendo
Emittente
PR News Wire
1.00
0
26/02/2025
Farmaceutica
Sanità
Biologia
Adcendo ApS Announces U.S. FDA Clearance of IND Application for Phase I Tiffany-01 Trial of ADCE-T02
Fonte
Adcendo
Emittente
PR News Wire
1.00
0
Press Release cover image
25/11/2024
Farmaceutica
Sanità
Finanza
Banca
Mutui
Risparmio/Affari personali
Leasing
Gestione dei titoli obbligazionari
Fondi di investimento
Euro-obbligazioni
Biologia
Adcendo ApS Completes Oversubscribed $135 Million Series B Financing to Advance First-in-class ADC Pipeline
Fonte
Adcendo
Emittente
PR News Wire
1.00
0
08/10/2024
Farmaceutica
Sanità
Biologia
Adcendo Announces US FDA Clearance of IND Application for Phase I/II First-in-Human ADCElerate-01 Trial of ADCE-D01 (uPARAP Receptor Targeting ADC) Trial in Patients With Metastatic and/or Unresectable Soft Tissue Sarcoma (STS)
Fonte
Adcendo
Emittente
PR News Wire
1.00
0
20/08/2024
Farmaceutica
Sanità
Economia
Brevetti, marchi e copyright
Biologia
Adcendo ApS and Multitude Therapeutics Inc. Announce Global Development and Commercialization Agreement on First-in-class ADC Drug Candidate Targeting Tissue Factor
Fonte
Adcendo
Emittente
PR News Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0